Low serum acylated ghrelin levels are associated with the development of cardiovascular disease in hemodialysis patients

Chia Chi Chou, Chyi-Huey Bai, Shiow Chwen Tsai, Mai-Szu Wu

研究成果: 雜誌貢獻文章

12 引文 (Scopus)

摘要

Background Ghrelin has a protective effect on endothelial cells. Endothelial cell dysfunction is associated with cardiovascular disease (CVD) and CVD remains the leading cause of morbidity in hemodialysis (HD) patients. Acylated ghrelin (A-Ghr) is the functional form of ghrelin, so we hypothesized that A-Ghr is associated with the occurrence of CVD in HD patients. Methods We conducted a prospective cohort study in 412 HD patients. The cohort was sub-grouped into low and high A-Ghr groups according to the median A-Ghr level of 4.88 pg/mL. The association between the low/high A-Ghr groups and the incidence of CVD were analyzed. Results The HD patients in a low A-Ghr group had a greater risk of incidental CVD than those in a high A-Ghr ghrelin. This association remained significant after the adjustment for possible confounding factors, including age, gender, HD duration, BMI, diabetes, albumin, nPCR and Charlson's comorbidity index score. Conclusion It appears that a low serum A-Ghr level is associated with the development of CVD in HD patients.
原文英語
頁(從 - 到)2057-2064
頁數8
期刊Internal Medicine
49
發行號19
DOIs
出版狀態已發佈 - 2010

指紋

Ghrelin
Renal Dialysis
Cardiovascular Diseases
Serum
Endothelial Cells
Age Factors
Comorbidity
Albumins
Cohort Studies
Prospective Studies
Morbidity

ASJC Scopus subject areas

  • Internal Medicine

引用此文

Low serum acylated ghrelin levels are associated with the development of cardiovascular disease in hemodialysis patients. / Chou, Chia Chi; Bai, Chyi-Huey; Tsai, Shiow Chwen; Wu, Mai-Szu.

於: Internal Medicine, 卷 49, 編號 19, 2010, p. 2057-2064.

研究成果: 雜誌貢獻文章

@article{55ed980ccd454a46bd145424d5169074,
title = "Low serum acylated ghrelin levels are associated with the development of cardiovascular disease in hemodialysis patients",
abstract = "Background Ghrelin has a protective effect on endothelial cells. Endothelial cell dysfunction is associated with cardiovascular disease (CVD) and CVD remains the leading cause of morbidity in hemodialysis (HD) patients. Acylated ghrelin (A-Ghr) is the functional form of ghrelin, so we hypothesized that A-Ghr is associated with the occurrence of CVD in HD patients. Methods We conducted a prospective cohort study in 412 HD patients. The cohort was sub-grouped into low and high A-Ghr groups according to the median A-Ghr level of 4.88 pg/mL. The association between the low/high A-Ghr groups and the incidence of CVD were analyzed. Results The HD patients in a low A-Ghr group had a greater risk of incidental CVD than those in a high A-Ghr ghrelin. This association remained significant after the adjustment for possible confounding factors, including age, gender, HD duration, BMI, diabetes, albumin, nPCR and Charlson's comorbidity index score. Conclusion It appears that a low serum A-Ghr level is associated with the development of CVD in HD patients.",
keywords = "Cardiovascular disease, Ghrelin, Hemodialysis",
author = "Chou, {Chia Chi} and Chyi-Huey Bai and Tsai, {Shiow Chwen} and Mai-Szu Wu",
year = "2010",
doi = "10.2169/internalmedicine.49.3047",
language = "English",
volume = "49",
pages = "2057--2064",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "19",

}

TY - JOUR

T1 - Low serum acylated ghrelin levels are associated with the development of cardiovascular disease in hemodialysis patients

AU - Chou, Chia Chi

AU - Bai, Chyi-Huey

AU - Tsai, Shiow Chwen

AU - Wu, Mai-Szu

PY - 2010

Y1 - 2010

N2 - Background Ghrelin has a protective effect on endothelial cells. Endothelial cell dysfunction is associated with cardiovascular disease (CVD) and CVD remains the leading cause of morbidity in hemodialysis (HD) patients. Acylated ghrelin (A-Ghr) is the functional form of ghrelin, so we hypothesized that A-Ghr is associated with the occurrence of CVD in HD patients. Methods We conducted a prospective cohort study in 412 HD patients. The cohort was sub-grouped into low and high A-Ghr groups according to the median A-Ghr level of 4.88 pg/mL. The association between the low/high A-Ghr groups and the incidence of CVD were analyzed. Results The HD patients in a low A-Ghr group had a greater risk of incidental CVD than those in a high A-Ghr ghrelin. This association remained significant after the adjustment for possible confounding factors, including age, gender, HD duration, BMI, diabetes, albumin, nPCR and Charlson's comorbidity index score. Conclusion It appears that a low serum A-Ghr level is associated with the development of CVD in HD patients.

AB - Background Ghrelin has a protective effect on endothelial cells. Endothelial cell dysfunction is associated with cardiovascular disease (CVD) and CVD remains the leading cause of morbidity in hemodialysis (HD) patients. Acylated ghrelin (A-Ghr) is the functional form of ghrelin, so we hypothesized that A-Ghr is associated with the occurrence of CVD in HD patients. Methods We conducted a prospective cohort study in 412 HD patients. The cohort was sub-grouped into low and high A-Ghr groups according to the median A-Ghr level of 4.88 pg/mL. The association between the low/high A-Ghr groups and the incidence of CVD were analyzed. Results The HD patients in a low A-Ghr group had a greater risk of incidental CVD than those in a high A-Ghr ghrelin. This association remained significant after the adjustment for possible confounding factors, including age, gender, HD duration, BMI, diabetes, albumin, nPCR and Charlson's comorbidity index score. Conclusion It appears that a low serum A-Ghr level is associated with the development of CVD in HD patients.

KW - Cardiovascular disease

KW - Ghrelin

KW - Hemodialysis

UR - http://www.scopus.com/inward/record.url?scp=77958103211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958103211&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.49.3047

DO - 10.2169/internalmedicine.49.3047

M3 - Article

C2 - 20930430

AN - SCOPUS:77958103211

VL - 49

SP - 2057

EP - 2064

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 19

ER -